Autologous cytolytic T lymphocytes recognize a MAGE‐1 nonapeptide on melanomas expressing HLA‐Cw* 1601
暂无分享,去创建一个
P. Bruggen | T. Boon | M. Sensi | J. Szikora | M. Somville | P. Boël | C. Wildmann
[1] J. Bodmer,et al. Nomenclature for Factors of the HLA System, 1994 , 1994, Human immunology.
[2] F. Brasseur,et al. Expression of mage genes by non‐small‐cell lung carcinomas , 1994, International journal of cancer.
[3] H. Grey,et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[4] P. Romero,et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.
[5] V. Engelhard,et al. Structure of peptides associated with class I and class II MHC molecules. , 1994, Annual review of immunology.
[6] P. Bruggen,et al. Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.
[7] S. H. van der Burg,et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.
[8] P. Coulie,et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.
[9] S. H. van der Burg,et al. Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes , 1993, European journal of immunology.
[10] P. Romero,et al. The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. , 1993, International journal of cancer.
[11] H. Stauss,et al. Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein , 1993, The Journal of experimental medicine.
[12] J. Bodmer,et al. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[13] M. Aidoo,et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria , 1992, Nature.
[14] P. Chomez,et al. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. , 1992, International journal of cancer.
[15] Catia,et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E , 1992, The Journal of experimental medicine.
[16] P. Parham,et al. Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C , 1992, The Journal of experimental medicine.
[17] S. Roman-Roman,et al. An experimentally validated panel of subfamily‐specific oligonucleotide primers (Vα1‐w29/Vβ1‐w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction , 1992, European journal of immunology.
[18] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[19] Timothy E. Elliott,et al. A quantitative assay of peptide‐dependent class I assembly , 1991, European journal of immunology.
[20] B. Moss,et al. An HLA-C-restricted CD8+ cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag , 1991, Journal of virology.
[21] H. Rammensee,et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.
[22] H. Schluesener,et al. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins , 1991, The Journal of experimental medicine.
[23] T. Boon,et al. Antigens recognized on a melanoma cell line by autologous cytolytic T lymphocytes are also expressed on freshly collected tumor cells , 1990, European journal of immunology.
[24] R. Fauchet,et al. Presence on a human melanoma of multiple antigens recognized by autologous CTL , 1989, International journal of cancer.
[25] R. Demars,et al. Restriction of Epstein-Barr virus-specific cytotoxic T cells by HLA-A, -B, and -C molecules. , 1989, Human immunology.
[26] K. Kano,et al. The structure and expression of genes encoding serologically undetected HLA-C locus antigens. , 1989, Journal of immunology.
[27] R. Demars,et al. Sequence and gene transfer analyses of HLA-CwBL18 (HLA-C blank) and HLA-Cw5 genes. Implications for the control of expression and immunogenicity of HLA-C antigens. , 1989, Journal of immunology.
[28] M. Hansen,et al. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.
[29] T. Boon,et al. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[30] C. Slingluff,et al. Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases. , 1988, Journal of the National Cancer Institute.
[31] C. Slingluff,et al. Autologous lymph node cell‐derived tumor‐specific cytotoxic t‐cells for use in adoptive immunotherapy of human melanoma , 1988, Cancer.
[32] H. Ploegh,et al. Allele and locus‐specific differences in cell surface expression and the association of HLA class I heavy chain with β2‐microglobulin: differential effects of inhibition of glycosylation on class I subunit association , 1988, European journal of immunology.
[33] W. Linehan,et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] P. Chomez,et al. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[35] B. Seed,et al. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[36] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[37] R. Devos,et al. Production of stable cytolytic T‐cell clones directed against autologous human melanoma , 1987, International journal of cancer.
[38] T. Espevik,et al. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.
[39] A. McMichael,et al. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides , 1986, Cell.
[40] L. G. Davis,et al. Guanidine Isothiocyanate Preparation of Total RNA , 1986 .
[41] L. G. Davis,et al. Basic methods in molecular biology , 1986 .
[42] J. Davey,et al. Cytotoxic T cells recognize fragments of the influenza nucleoprotein , 1985, Cell.
[43] L. Old,et al. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[44] B. Mukherji,et al. Clonal analysis of cytotoxic T cell response against human melanoma , 1983, The Journal of experimental medicine.
[45] G. Bonnard,et al. Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2 , 1982, International journal of cancer.
[46] R. Sheppard,et al. Peptide synthesis. Part 2. Procedures for solid-phase synthesis using Nα-fluorenylmethoxycarbonylamino-acids on polyamide supports. Synthesis of substance P and of acyl carrier protein 65–74 decapeptide , 1981 .
[47] C. Uyttenhove,et al. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis , 1980, The Journal of experimental medicine.
[48] C. Barnstable,et al. Molecular structure of human histocompatibility antigens: the HLA‐C series , 1977, European journal of immunology.